Segantii Capital Management LTD Has Lowered Gilead Sciences (GILD) Stake, Manhattan Associates, Inc. (MANH) Had 3 Bulls

June 20, 2017 - By Marguerite Chambers

Among 5 analysts covering Manhattan Assoc (NASDAQ:MANH), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Manhattan Assoc had 9 analyst reports since July 22, 2015 according to SRatingsIntel. The company was initiated on Tuesday, January 12 by Brean Capital. Raymond James downgraded the shares of MANH in report on Monday, January 9 to “Mkt Perform” rating. The firm has “Buy” rating by Benchmark given on Wednesday, October 21. William Blair downgraded the shares of MANH in report on Thursday, April 28 to “Market Perform” rating. The rating was initiated by Lake Street with “Buy” on Monday, October 19. William Blair initiated the shares of MANH in report on Tuesday, September 29 with “Outperform” rating. Benchmark maintained the shares of MANH in report on Wednesday, July 22 with “Buy” rating. Benchmark maintained Manhattan Associates, Inc. (NASDAQ:MANH) on Wednesday, February 1 with “Buy” rating. See Manhattan Associates, Inc. (NASDAQ:MANH) latest ratings:

01/02/2017 Broker: Benchmark Rating: Buy Old Target: $71 New Target: $65 Maintain
09/01/2017 Broker: Raymond James Old Rating: Outperform New Rating: Mkt Perform Downgrade

Segantii Capital Management Ltd decreased Gilead Sciences Inc (GILD) stake by 36% reported in 2016Q4 SEC filing. Segantii Capital Management Ltd sold 18,000 shares as Gilead Sciences Inc (GILD)’s stock declined 8.05%. The Segantii Capital Management Ltd holds 32,000 shares with $2.31M value, down from 50,000 last quarter. Gilead Sciences Inc now has $83.80B valuation. The stock increased 1.09% or $0.7 during the last trading session, reaching $64.82. About 819 shares traded. Gilead Sciences, Inc. (NASDAQ:GILD) has declined 21.80% since June 20, 2016 and is downtrending. It has underperformed by 38.50% the S&P500.

Investors sentiment decreased to 0.8 in 2016 Q4. Its down 0.17, from 0.97 in 2016Q3. It worsened, as 44 investors sold Manhattan Associates, Inc. shares while 115 reduced holdings. 39 funds opened positions while 88 raised stakes. 68.75 million shares or 0.69% less from 69.23 million shares in 2016Q3 were reported. 5,780 were accumulated by Teacher Retirement Systems Of Texas. Etrade Cap Ltd Liability Company reported 0.05% in Manhattan Associates, Inc. (NASDAQ:MANH). First Quadrant L P Ca invested in 48,847 shares. Panagora Asset Inc owns 0% invested in Manhattan Associates, Inc. (NASDAQ:MANH) for 3,191 shares. Huntington Fincl Bank holds 5,679 shares or 0.01% of its portfolio. Jpmorgan Chase And has 0.01% invested in Manhattan Associates, Inc. (NASDAQ:MANH). Thrivent For Lutherans reported 88,349 shares. Pub Employees Retirement Association Of Colorado accumulated 208,002 shares. United Kingdom-based Gsa Partners Ltd Liability Partnership has invested 0.05% in Manhattan Associates, Inc. (NASDAQ:MANH). The New York-based Sg Americas Lc has invested 0.01% in Manhattan Associates, Inc. (NASDAQ:MANH). Dimensional Fund Advsrs Limited Partnership reported 536,484 shares. Rhode Island-based Amica Pension Fund Board Of Trustees has invested 0.04% in Manhattan Associates, Inc. (NASDAQ:MANH). Soros Fund Management Ltd Co owns 6,200 shares. Axa reported 295,727 shares. Keybank National Association Oh invested in 0% or 7,451 shares.

The stock increased 0.51% or $0.24 during the last trading session, reaching $47.35. About shares traded. Manhattan Associates, Inc. (NASDAQ:MANH) has declined 22.39% since June 20, 2016 and is downtrending. It has underperformed by 39.09% the S&P500.

Manhattan Associates, Inc. is a developer and well-known provider of supply chain commerce solutions. The company has market cap of $3.31 billion. The Firm operates through three geographical divisions: the Americas, Europe, Middle East and Africa (EMEA), and the Asia Pacific (APAC). It has a 26.96 P/E ratio. It is engaged in developing, selling, deploying, servicing and maintaining software solutions designed to manage supply chains, inventory and omni-channel activities for retailers, wholesalers, manufacturers, logistics providers and other organizations.

Investors sentiment decreased to 0.7 in Q4 2016. Its down 0.23, from 0.93 in 2016Q3. It turned negative, as 106 investors sold GILD shares while 656 reduced holdings. 111 funds opened positions while 421 raised stakes. 950.84 million shares or 0.69% more from 944.29 million shares in 2016Q3 were reported. 1.13M were reported by Brandywine Mngmt Ltd. South Dakota Inv Council reported 945,295 shares. Pinebridge Invests Ltd Partnership reported 19,314 shares. Contrarius Invest accumulated 33,144 shares. Grisanti Capital Mgmt Lc owns 92,398 shares or 2.97% of their US portfolio. Swedbank owns 2.60M shares for 1.47% of their portfolio. Lazard Asset Ltd holds 0% or 7,709 shares in its portfolio. Gamble Jones Investment Counsel holds 41,342 shares. Tokio Marine Asset Management Limited reported 25,653 shares. Foundry Ptnrs Ltd Limited Liability Company holds 0.02% or 7,922 shares. Denver Inv Advsrs Ltd Liability Co, Colorado-based fund reported 6,448 shares. Renaissance Technologies Llc stated it has 5.27M shares. Ashmore Group Inc Public Ltd holds 0.05% or 1,000 shares. Moreover, West Oak Capital Ltd Llc has 0% invested in Gilead Sciences, Inc. (NASDAQ:GILD). Verition Fund Limited Liability Corp invested 0.16% in Gilead Sciences, Inc. (NASDAQ:GILD).

Since January 3, 2017, it had 0 insider purchases, and 11 insider sales for $33.68 million activity. Another trade for 5,000 shares valued at $337,392 was sold by Alton Gregg H. Shares for $1.41 million were sold by WILSON GAYLE E on Thursday, February 23. On Wednesday, March 1 the insider MARTIN JOHN C sold $5.16 million. 9,943 shares were sold by Cogan John Francis, worth $668,667 on Tuesday, May 9.

Analysts await Gilead Sciences, Inc. (NASDAQ:GILD) to report earnings on July, 24. They expect $2.13 EPS, down 29.70% or $0.90 from last year’s $3.03 per share. GILD’s profit will be $2.75 billion for 7.61 P/E if the $2.13 EPS becomes a reality. After $2.20 actual EPS reported by Gilead Sciences, Inc. for the previous quarter, Wall Street now forecasts -3.18% negative EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: